Street Calls of the Week

Monday – Lumentum Holdings

What’s the full story? Evercore has launched coverage on Lumentum Holdings Inc (NASDAQ:LITE) with an Outperform rating and a $1,100 price target. The AI boom has exposed a supply-chain bottleneck: silicon processors are fast, but data cannot be moved between them fast enough. Connecting those compute clusters requires indium phosphide lasers, a scarce and capital-intensive component where demand is running 30% ahead of supply. Lumentum controls that critical chokepoint, giving it pricing power and shifting margin upside to vertically integrated incumbents.

Evercore forecasts the optical AI market will surge from $18 billion to more than $90 billion by 2030. Optical content is scaling up inside racks, across clusters, and between data centers, which protects Lumentum from reliance on any single customer. Meanwhile, demand for optical circuit switching is compounding at over 150%, underpinned by two decades of proprietary mirror technology developed in-house.

The firm models fiscal 2028 earnings per share of $35, with upside potential to $50, while seeing gross margins expand to 54%. When a company controls the bottleneck, it effectively prints money, and Evercore recommends buying that bottleneck.

Tuesday – Sempra Energy

What’s the full story? Jefferies has upgraded Sempra Energy (NYSE:SRE) to Buy. The market is worried about Texas transmission capital-expenditure delays and a stalled California legislative bill, pushing SRE to a 14% earnings discount versus its electric utility peers. That panic creates cheap assets. Sempra’s Texas infrastructure pipeline remains largely intact even if high-voltage line projects take longer, and its California operations do not carry the kind of wildfire liability that is hurting PG&E and Edison International.

Jefferies sees a classic mispricing for patient investors. A full valuation recovery depends on clarity coming out of the Texas legislative session, but waiting for certainty means paying a much higher price. Buying into the panic before regulators finish their work is where the profit lies.

Wednesday – Eyepoint Pharma

What’s the full story? TD Cowen has downgraded Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) to Hold and slashed its price target to $4. The failed Phase III LUGANO trial has weakened confidence in the upcoming LUCIA study. Management attributes the bad data to a statistical fluke, citing nine unlucky patients from a poor randomization mix. That explanation may have some merit, but regulators and Wall Street rarely accept bad luck—they focus on poor trial outcomes.

Even after reworking the numbers and excluding the worst 4% of patients, the post-hoc vision data still look weak. The analyst notes the FDA seldom accepts statistical reanalyses as proof of efficacy. For Duravyu to survive, LUCIA would need exceptionally strong results to rescue a pooled analysis—a difficult task given that patient vision curves steadily deteriorate once the initial drug loading effect fades.

The analyst has removed wet AMD sales completely from the model. EyePoint’s remaining thesis now rests on distant trials for diabetic macular edema. Hope still exists, but at $4 per share, the market wants hard evidence rather than explanations.

Thursday – Covista Inc.

What’s the full story? Truist has downgraded Covista Inc (NYSE:CVSA) to Hold from Buy, while keeping its $140 price target intact. The easy gains have already been captured, and the market has fully priced in the turnaround narrative for the Chamberlain division. Panic and hype can run hot, but valuation math stays cold and unyielding.

The report expresses little concern that generative AI will wipe out Covista’s student recruitment pipeline. However, collateral damage across the wider education sector could keep valuation multiples below their five-year historical averages. Wall Street loves a good narrative, but even the most compelling story cannot lift a stock when the rest of its industry is dragging down the entire group.

Truist struggles to see how the stock can achieve another two turns of multiple expansion toward last summer’s peak valuations. Chasing fully priced rallies is a quick way to lose money, so the firm is stepping aside and letting someone else pay top dollar.

Friday – Sonida Senior Living

What’s the full story? Baird has upgraded Sonida Senior Living Inc (NYSE:SNDA) to Outperform with a $43 price target. The firm identifies a clear macroeconomic trade: senior housing operators hold significant pricing power as the aging population collides with limited bed supply. Sonida’s newly built operating platform gives it the scale to generate fresh returns from its existing real estate while also pursuing attractively priced acquisitions.

The report notes that the recent merger integration is proceeding smoothly, which sets the stage for renewed external growth. The flywheel is turning, and management appears ready to add more leveraged balance-sheet risk to the mix.

The debt load certainly looks substantial, yet virtually no debt matures until 2028. Baird expects organic growth to gradually reduce that leverage before lenders come calling. Leverage works until it doesn’t, but for now, demographics favor the speculator.